Whereas an association between PD-L1 expression and clinical response has been detected for specific tumor types such as non–small cell lung cancer (NSCLC), results from several prospective trials suggest that PD-L1 expression may not be a robust predictor of the response to PD-1 antibodies in all cancer types (3–6). Here, CD274 is linked to neoplasm.